Noxopharm Ltd (ASX:NOX) CEO Dr Graham Kelly provides the business case for the Company's subsidiary, Pharmorage, a company focused on inflammation and autoimmune diseases. He says the chance to venture into this space came about thanks to a research discovery that could have major commercial potential. By establishing two separate entities, Noxopharm is free to advance its oncology business, while the Pharmorage subsidiary can pursue a commercial relationship with the Australian research institute.
Noxopharm CEO discusses subsidiary Pharmorage and its focus on inflammation and autoimmune diseases
